Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CB101
- Development stage
- Preclinical
- Lead developer
- CentricsBio
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
**CB101** is CureBiotech's proprietary, intratumoral, controlled-release hydrogel formulation of **resiquimod**, a small-molecule toll-like receptor 7 and toll-like receptor 8 agonist. The polymer-matrix formulation is intended to retain resiquimod locally within tumors, activate innate immune signaling and dendritic-cell function, and improve antitumor immune responses while limiting systemic immune toxicity. It has been evaluated with hypofractionated radiation therapy in a pilot study in dogs with head and neck cancer, and CureBiotech has also described preclinical development with radiation therapy for human head and neck squamous cell carcinoma. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12318883/))
- Other names
- CBC101CBC-101CBC 101
Beyond the preview
Go deeper on CB101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CB101.